We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

153 hedge funds and large institutions have $396M invested in Sciclone Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 55 increasing their positions, 49 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

544% more call options, than puts

Call options by funds: $290K | Put options by funds: $45K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

22% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 49

1% more funds holding

Funds holding: 152 → 153 (+1)

4.36% less ownership

Funds ownership: 76.15% → 71.78% (-4.4%)

28% less capital inflows, than outflows

Capital inflows: $47.5M | Capital outflows: $66.2M

Holders
153
Holders Change
+1
Holders Change %
+0.66%
% of All Funds
3.82%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
28
Increased
55
Reduced
49
Closed
23
Calls
$290​K
Puts
$45​K
Net Calls
+$245​K
Net Calls Change
+$171​K

SCLN Hedge Fund Activity: Q4 2016 in Review

153 of the 4,009 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals (SCLN) for Q4 2016, worth a combined $396M — down 0.7% from $398M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new SCLN positions and 23 closed out — a net gain of 5 holders — while 55 added to existing stakes and 49 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $12.5M. The largest seller was Numeric Investors, cutting an estimated $16.2M.

  • 153 institutional investors held Sciclone Pharmaceuticals (SCLN) as of Q4 2016, up from 152 in Q3 2016.
  • Funds reported $396M of Sciclone Pharmaceuticals stock for Q4 2016, down 0.7% quarter-over-quarter.
  • 28 funds opened new Sciclone Pharmaceuticals positions in Q4 2016 and 23 closed out, a net change of +5 holders.
  • The largest Sciclone Pharmaceuticals buyer in Q4 2016 was Stonepine Capital Management, an estimated $12.5M added.
  • The largest Sciclone Pharmaceuticals seller in Q4 2016 was Numeric Investors, an estimated $16.2M sold.

Based on aggregated 13F filings for Q4 2016.